Filing Flows › Beam Therapeutics (BEAM) › Q3 2026
Beam Therapeutics (BEAM) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Beam Therapeutics (BEAM) reported revenue of $307K for the third quarter 2026 (Q3 2026), -97% from a year earlier and -37% from the quarter before.
Beam Therapeutics, Q3 2026: revenue $307K (-97% year over year), net loss $134M, operating cash flow −$111M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $307K | -37% | -97% |
| Operating profit | −$141M | — | — |
| Net earnings | −$134M | — | — |
| Operating cash flow | −$111M | — | — |
What changed
Revenue was $307K in Q3 2026, down 97% year over year and down 37% from the previous quarter.
Operating costs exceeded revenue by $141.3M, an operating margin of -46033.2%. Total costs grew 4% against a revenue fall of 97%. The fastest-growing cost line was General & admin (+18%). The quarter ended with a net loss of $134.4M, wider than the previous quarter's $122.7M loss.
Operating cash flow was −$110.7M. Non-cash charges added back $5.4M of depreciation and $18.6M of share-based compensation. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$112.0M.
Questions
What was Beam Therapeutics' revenue in the third quarter 2026?
Beam Therapeutics (BEAM) reported revenue of $307K for the third quarter 2026 (Q3 2026), -97% from a year earlier and -37% from the quarter before.
Source: Beam Therapeutics 10-Q on SEC EDGAR.